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Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, 
with unknown etiology in which both genetic and environmental factors are 
thought to be involved. The HLA system provides a set of genetic markers 
which lend themselves to systematic study. The disease also has variable 
clinical manifestations, ranging from a relapsing-remitting course to a chronic 
progressive disease. 
In this article we review HLA profile and clinical presentation of the disease 
from current available data in Iran. 
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Introduction 
Multiple sclerosis (MS) can be regarded as an organ-specific inflammatory disease 
probably resulting from an aberrant immune response to myelin antigens (1-4). It 
is a disease of unknown etiology in which both genetic and environmental factors 
are thought to be involved (5). The HLA system provides a set of genetic markers 
which lend themselves to systematic study. Evidence continues to accumulate that 
MS populations differ from local controls in their HLA allele composition (6). 
This association varies in different parts of the world probably due to varying 
racial susceptibility to MS(7-8). Genetic analyses have suggested that the major 
histocompatibility complex (MHC)/HLA region on chromosome 6p21 contains an 
MS-predisposing component (9). Which of the many genes present in this region is 
responsible for MS susceptibility is still an unsettled issue. However results from 
genomic screens suggest that a number of genes of varying and interacting effects 
will be implicated and these searches reinforce the genetic epidemiology of the 
disease (10). 
The condition is diagnosed clinically from the demonstration of white matter (WM) 
dysfunction separated in time and space (11). It is a cause of chronic neurological 
disability in young and middle-aged adults with and unequal distribution worldwide 
(2, 12). The variation in prevalence and clinical pattern according to geographical 
location, probably related to ethnic and environmental factors, has been observed in 
several studies (13-14). The prevalence is thought to be low in Iran (15) an in other 
middle-eastern countries (16-20). At present, the current impression in Iran is that 
more cases are being diagnosed. 
The aim of this communication is to highlight the HLA types and clinical course of 
the disease and its pattern of presentation in the largest sample of cases managed so 
far in Iran (15, 21). 
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Factors Contributing to disease susceptibility  
A- Environmental factors: Classic studies indicate that 
MS exhibits distinct geographic clustering within the 
temperate zones in northern and southern hemisphere 
(22). Migration studies have been informative regarding 
the interaction of genetic susceptibility and environment. 
An individual who moves from a high-risk to a low-
risk area during childhood will acquire a low-risk of 
developing MS (23). By contrast individual moving after 
adolescence retain the risk of the original location. 
B- Genes and susceptibility to MS: the balance of 
evidence relating to the etiology of multiple sclerosis 
favours an interplay between genetic susceptibility 
and environmental trigger. Just as the twin studies 
show clearly that almost 60% of monozygotic pairs are 
not concordant for multiple sclerosis (24-26) so is the 
low concordance rate in dizygonic twins, the rarity of 
conjugal multiple sclerosis (27) the lack of a birth order 
effect (28) and the identification of resistant groups 
living in high prevalence zones, all argue against a 
purely transmissible factor (29). A simple view would be 
that, of the candidate genes which have been examined 
as markers of susceptibility, only the DR15 class 2 major 
histocompatibility complex (MHC) allele association 
in northern Europeans holds up to critical analysis. 
The specifically different associations with DR4 in 
Japanese (30) and Jordanians (31) have never been 
confirmed although multiple sclerosis does appear be 
DR4 associated in Sardinians (8). There is no evidence 
that any genetic marker, acting alone or in combination, 
protects individuals from development of the disease. 
Reports that the severity of multiple sclerosis correlates 
with the presence of specific susceptibility alleles, or that 
the primary progressive form of the disease is associated 
with a specifically different set of susceptibility markers 
(32-33), remain unconfirmed.
The role of the HLA system in conferring susceptibility 
to MS has been demonstrated by population association 
studies, but these do not resolve the question of which 
class 2 region allele makes the primary contribution. 
The association also is varied in different races. For 
these reasons we studied the role of HLA system in 79 
Caucasoid Iranian patients with definite MS (15).
Seventy- four patients were classified as having 
relapsing-remitting (RR) MS, with distinct (11) attacks 
and stable phases in between. This group consisted of 48 
females and 26 males with an age range of 18 to 50 years 
(mean 31  7.3), disease duration of 4.2 3.3 years and 
an EDSS of 1.9 1.1. 
Five patients were classified as primary progressive 
(PP) MS (11) having had a steady progressive course. 
This group consisted of four females and one male with 
age range of 37 to 61 years (mean 48.4 9.9), disease 
duration of 8.6 6.8 and EDSS of 4.3 2.3. 
From 51 antigens tested and compared with 100 controls 
(13A, 18B, 5C, 12 DR, 3 DQ), it was found that the 
distribution of HLA antigens show a preponderance for 
HLA-DR15 and to a lesser degree for HLA- DR2 and 
HLA- A24 in MS patients. On the other hand, HLA-
B15, B40, DR4, DR52 and DQ3 are significantly under- 
represented in MS. 
The same was true for HLA-A28, B5, B14, and CW2 
but to a lesser degree. Segregating patients according to 
age of onset, revealed no significant differences in the 
distribution of HLA antigens. Thus the 65 Ms patients 
with age at onset before 35 years had HLA- DR15, DR2 
and A24 frequencies of 36.5, 43 and 31.08% respectively. 
Corresponding frequencies for the 14 patients with onset 
after 35 years were 37, 43 and 29.9% respectively. When 
HLA types were analysed for RR and PP subgroups, no 
significant differences were noted.  
No MS patients had severe disease with a Kutzke score 
of five or more within 5 years of their first symptoms. 
Clinical symptoms and physical findings 
 Although the clinical syndrome of MS is classically 
described as a relapsing- remitting disorder that 
affects multiple white matter tracts within the CNS, 
with usual onset in young adults, the disorder displays 
marked clinical heterogeneity. This variability 
includes age of onset, mode of initial manifestation, 
frequency, severity and sequealae of relapses, extent 
of progression and certain specific clinical and 
neuro-immunological features. For these reasons we 
decided to study the clinical course and pattern of 
presentation of the disease in an Iranian MS population. 
The study period was form July 1996 to July 2001, 
during which 200 cases ware evaluated (21). 
The RR from was the most common clinical presentation, 
with 179 case(88%) followed by PP with 14 cases (7%) 
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and SP with 10 cases (5%). the mean age of onset for 
the entire group of 200 patients was 27 7.4 years, with 
disease duration of 5.5 4.7 years and an EDSS score 
of 2.1 1.4. 
The PP group had a higher age at onset (37.1 8.8 years) 
with female preponderance (10 out of 14). In 12 cases, 
spinal signs were first presented in the form of paraparesis 
with or without sphincter or sensory disturbance. In two 
cases, the presenting symptom was of cerebellar nature 
followed by spinal signs. 
Women represented 72% of cases giving a gender ratio 
of 2.5:1 female: male. While the yearly number of attacks 
in the RR groups was 0.4, SP patients had an average of 
1.2 attacks per year, for their average of 10 6.1 years 
before entering this phase. Almost all of the SP cases had 
spinal or cerebellar signs at the onset of the disease.
The most common presenting symptoms were weakness 
in one or more limbs (33%) followed by sensory 
impairment (24%), sphincter disturbance (20%), Visual 
impairment (20%), Ataxia (15%), vertigo (10%), 
Diplopia (5%), Bell’s palsy (3%) and seizure (3%). 
Twenty- seven percent of cases had more than one 
symptom. Eight patients had optico- spinal presentation 
of RR type with simultaneous or consecutive visual 
and spinal impairments of motor and/or sensory nature, 
with mean disease duration of three years and an EDSS 
score of 1.3. Ninety per cent of patients were of middle- 
income class, 65% had a high school diploma and 30% 
were educated at university level. Ten patients (5%) had 
a positive family history, each one with one first- degree 
affected relative. While 28(14%) benign cases were 
recorded (34) with an EDSS score of 3 or less after 10 
years, 24 patients had disease duration of five years or 
more with an EDSS score of 2 or less. 
Discussion  
HLA typing, natural course and clinical findings of 79 
and 200 definite MS cases in Iran were respectively 
reviewed (15, 21). 
Results, drawn from our 79 Iranian MS patients reveal 
an association between MS and HLA types- A24, DR2, 
and DR15, each with a relative risk of 1.9 times that 
of controls. This genetically determined increased risk 
is best explained by assuming the existence of an MS 
susceptibility gene which has been identified in linkage 
studies with HLA-DR15 and DR2 loci on chromosome 
6. This association of DR2 and DR15 HLA types with 
MS in Iranian patients is in line with studies done in 
other parts of the world (34-37). In the analysis of HLA 
class I, we found a positive association with A24 but 
no association with B locus alleles. The association of 
HLA-A locus in Iranian MS differs from previous studies 
in other parts of the world (35, 38-39) as well as Asian 
countries (40-41). In fact Indian investigators identified 
an association between HLA B12 and MS (40). 
Of interest is the under-representation of the following 
alleles in Iranian MS patients: HLA-A28, B5, B14, 
CW2 (P<0.05) and HLA-B15, B40, DR-4, DR-52, and 
DQ3(P<0.005). 
Whether these alleles have any protective role against 
MS in this geographic region to be determined. 
 Iran is traditionally though to be situated in a low risk 
zone for MS (21). Here MS presents with involvement 
of multiple sites in the central nervous system (CNS), 
including the cerebrum, cerebellum or brainstem, which 
is similar to its behavior in the Caucasian population. 
Having RRMS as the most frequent type of presentation, 
followed by the PP form with a higher age of onset 
and worse prognosis, and female preponderance in 
both types, are in agreement with European and Latin 
American Studies (42-45). The most common presenting 
symptoms of pyramidal and sensory involvement in the 
present cases have also been reported from neighboring 
Middle East countries and Europe (12, 42). Compared 
with the RR group, SP had more annual attacks with 
pyramidal or cerebellar dysfunction as their presenting 
signs. The presence of 28 patients with an EDSS score 
3 after 10 years and 24 with an EDSS score 2 after five 
years indicates a benign course for MS in this country. 
Optico-Spinal MS, which is a common presentation of 
the disease in Asian countries and is called Asian type 
(46), is not a prominent feature here, probably due to 
different HLA typing. 
It is believed that we are facing a rising incidence of 
MS similar to other countries (12, 45, 47). This may be 
explained by increased survival, improved laboratory and 
radiological diagnoses. However, a decreased number 
with SP form, which is a natural endpoint of the RR type, 
may indicate that more new cases are being diagnosed, 
and other possibilities should be looked for (21).    
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